We report here the preparation, physico-chemical characterization, and biological evaluation of a new liposome formulation as a tool for tumor angiogenesis inhibition. Liposomes are loaded with sunitinib, a tyrosine kinase inhibitor, and decorated with cyclo-aminoprolineRGD units (cAmpRGD), efficient and selective ligands for integrin αVβ3. The RGD units play multiple roles since they target the nanovehicles at the integrin αVβ3-overexpressing cells (e.g. activated endothelial cells), favor their active cell internalization, providing drug accumulation in the cytoplasm, and likely take part in the angiogenesis inhibition by interfering in the αVβ3-VEGFR2 cross-talk. Both in vitro and in vivo studies show a better efficacy of this integrated antiangiogenic tool with respect to the free sunitinib and untargeted sunitinib-loaded liposomes. This system could allow a lower administration of the drug and, by increasing the vector specificity, reduce side-effects in a prolonged antiangiogenic therapy.

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools / Bianchini, Francesca; De Santis, Augusta; Portioli, Elisabetta; Krauss, Irene Russo; Battistini, Lucia; Curti, Claudio; Peppicelli, Silvia; Calorini, Lido; D'Errico, Gerardino; Zanardi, Franca; Sartori, Andrea. - In: NANOMEDICINE. - ISSN 1549-9634. - 18:(2019), pp. 135-145. [10.1016/j.nano.2019.02.015]

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools

De Santis, Augusta;Krauss, Irene Russo;D'Errico, Gerardino;
2019

Abstract

We report here the preparation, physico-chemical characterization, and biological evaluation of a new liposome formulation as a tool for tumor angiogenesis inhibition. Liposomes are loaded with sunitinib, a tyrosine kinase inhibitor, and decorated with cyclo-aminoprolineRGD units (cAmpRGD), efficient and selective ligands for integrin αVβ3. The RGD units play multiple roles since they target the nanovehicles at the integrin αVβ3-overexpressing cells (e.g. activated endothelial cells), favor their active cell internalization, providing drug accumulation in the cytoplasm, and likely take part in the angiogenesis inhibition by interfering in the αVβ3-VEGFR2 cross-talk. Both in vitro and in vivo studies show a better efficacy of this integrated antiangiogenic tool with respect to the free sunitinib and untargeted sunitinib-loaded liposomes. This system could allow a lower administration of the drug and, by increasing the vector specificity, reduce side-effects in a prolonged antiangiogenic therapy.
2019
Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools / Bianchini, Francesca; De Santis, Augusta; Portioli, Elisabetta; Krauss, Irene Russo; Battistini, Lucia; Curti, Claudio; Peppicelli, Silvia; Calorini, Lido; D'Errico, Gerardino; Zanardi, Franca; Sartori, Andrea. - In: NANOMEDICINE. - ISSN 1549-9634. - 18:(2019), pp. 135-145. [10.1016/j.nano.2019.02.015]
File in questo prodotto:
File Dimensione Formato  
Nanomedicine 2019,18,135.pdf

solo utenti autorizzati

Descrizione: Nanomedicine 2019,18,135
Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 566.19 kB
Formato Adobe PDF
566.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/747268
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact